Literature DB >> 31694431

Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review.

Kirsten E J Wesenhagen1, Charlotte E Teunissen2, Pieter Jelle Visser1, Betty M Tijms1.   

Abstract

Alzheimer's disease (AD) is the most common cause of dementia and is characterized by aggregation of amyloid and tau proteins in the brain. Results from genetic studies suggest that the pathophysiology underlying AD is complex, but studying this complexity in patients remains difficult. The cerebrospinal fluid (CSF) proteome contains a large number of proteins that can reflect ongoing biological processes. Proteomics techniques can be used to measure many proteins simultaneously in individual patients and may therefore provide an opportunity to study AD disease mechanisms. Here, we review the CSF proteomics literature to identify proteins consistently associated with AD, and perform pathway analyses on these proteins to study which biological processes may be involved in the disease.We performed a literature search of studies that investigated CSF proteomic alterations related to AD. We included original research articles when they measured at least 10 proteins in (antemortem) CSF in at least 10 individuals with AD, mild cognitive impairment (MCI) or controls. We examined if proteins were consistently related to AD, defined as consistent increase or decrease in AD vs. controls across studies. Next, we used the proteins identified as input to pathway analyses using Reactome to investigate which biological processes were enriched.In total, 29 studies were included that investigated AD-related changes to the CSF proteome, including a total of 1434 individuals with AD (of whom 47.1% had a CSF biomarker profile and 9.6% a postmortem examination consistent with AD) and 1380 controls. The studies reported 1 to 138 proteins associated with AD, of which 97 proteins were reported by two or more studies. Among proteins that were measured in more than one study, 27 (27.8%) showed consistent increases, 15 (15.5%) consistent decreases and 55 (56.7%) had contrasting results. Pathway analyses showed that AD-related proteins were enriched for hemostasis, lipoprotein and extracellular matrix pathways.These results indicate that proteomic alterations in CSF associated with AD reflect involvement of various biological pathways. The frequent occurrence of inconsistent protein level changes reported by different studies suggests that additional biological and/or (pre)analytical factors may influence the CSF proteome in AD, which should be further investigated in order to improve understanding of the biological complexity underlying AD.

Entities:  

Keywords:  Alzheimer’s disease; biomarkers; cerebrospinal fluid; heterogeneity; proteomics

Mesh:

Substances:

Year:  2019        PMID: 31694431     DOI: 10.1080/10408363.2019.1670613

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  16 in total

Review 1.  Recent update on the heterogeneity of the Alzheimer's disease spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-12-17       Impact factor: 3.575

Review 2.  New insights into atypical Alzheimer's disease in the era of biomarkers.

Authors:  Jonathan Graff-Radford; Keir X X Yong; Liana G Apostolova; Femke H Bouwman; Maria Carrillo; Bradford C Dickerson; Gil D Rabinovici; Jonathan M Schott; David T Jones; Melissa E Murray
Journal:  Lancet Neurol       Date:  2021-03       Impact factor: 44.182

Review 3.  Knowledge gaps in Alzheimer's disease immune biomarker research.

Authors:  David G Morgan; Michelle M Mielke
Journal:  Alzheimers Dement       Date:  2021-05-13       Impact factor: 21.566

Review 4.  Developing the ATX(N) classification for use across the Alzheimer disease continuum.

Authors:  Harald Hampel; Jeffrey Cummings; Kaj Blennow; Peng Gao; Clifford R Jack; Andrea Vergallo
Journal:  Nat Rev Neurol       Date:  2021-07-08       Impact factor: 44.711

5.  Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds.

Authors:  Julia Remnestål; Sofia Bergström; Jennie Olofsson; Evelina Sjöstedt; Mathias Uhlén; Kaj Blennow; Henrik Zetterberg; Anna Zettergren; Silke Kern; Ingmar Skoog; Peter Nilsson; Anna Månberg
Journal:  Alzheimers Res Ther       Date:  2021-03-02       Impact factor: 6.982

6.  An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer's disease.

Authors:  Christopher Clark; Loïc Dayon; Mojgan Masoodi; Gene L Bowman; Julius Popp
Journal:  Alzheimers Res Ther       Date:  2021-04-01       Impact factor: 6.982

7.  Pilot proteomic analysis of cerebrospinal fluid in Alzheimer's disease.

Authors:  Justin McKetney; Daniel J Panyard; Sterling C Johnson; Cynthia M Carlsson; Corinne D Engelman; Joshua J Coon
Journal:  Proteomics Clin Appl       Date:  2021-04-26       Impact factor: 3.494

8.  Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease.

Authors:  Sofia Bergström; Julia Remnestål; Jamil Yousef; Jennie Olofsson; Ioanna Markaki; Stephanie Carvalho; Jean-Christophe Corvol; Kim Kultima; Lena Kilander; Malin Löwenmark; Martin Ingelsson; Kaj Blennow; Henrik Zetterberg; Bengt Nellgård; Frederic Brosseron; Michael T Heneka; Beatriz Bosch; Raquel Sanchez-Valle; Anna Månberg; Per Svenningsson; Peter Nilsson
Journal:  Ann Clin Transl Neurol       Date:  2021-06-15       Impact factor: 4.511

Review 9.  A comprehensive systematic review of CSF proteins and peptides that define Alzheimer's disease.

Authors:  Juan R Peinado; Yoana Rabanal-Ruiz; Cristina M Pedrero-Prieto; Sonia García-Carpintero; Javier Frontiñán-Rubio; Emilio Llanos-González; Cristina Aguilera García; Francisco J Alcaín; Iris Lindberg; Mario Durán-Prado
Journal:  Clin Proteomics       Date:  2020-06-05       Impact factor: 3.988

Review 10.  Biomarkers: Our Path Towards a Cure for Alzheimer Disease.

Authors:  Rawan Tarawneh
Journal:  Biomark Insights       Date:  2020-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.